May 25, 2023 5:00pm EDT Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO
Apr 28, 2023 12:00pm EDT Adaptimmune to Report Q1 2023 Financial and Business Updates on Friday, May 12, 2023
Apr 11, 2023 8:00am EDT Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
Mar 06, 2023 6:30am EST Adaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Update
Mar 06, 2023 6:00am EST Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
Feb 22, 2023 8:00am EST Adaptimmune to Report Q4 and Full Year 2022 Financial and Business Updates on Monday, March 6, 2023
Jan 09, 2023 8:00am EST Publication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcoma
Dec 23, 2022 1:20pm EST Adaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial Sarcoma
